Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16–26 years in Japan: a randomised, double-blind, placebo-controlled trial

The Lancet Infectious Diseases · Published 2026-08-01 · DOI 10.1016/s1473-3099(26)00291-4

Authors (12)

Koji Hisamoto, Masaki Yamanaka, Masayasu Nomura, Nobufumi Kanno, Anna R Giuliano, Keiko Wan, Yukako Fukao, Nobuyuki Oshima, Akira Wakana, Yoshiyuki Tanaka, Alain Luxembourg, Miyuki Sawata

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Hisamoto, K., Yamanaka, M., Nomura, M., et al. (2026). Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16–26 years in Japan: a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00291-4

Related articles